Cargando…

HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) remains a global medical problem. Programmed cell death protein 1 (PD-1) is a powerful weapon against many cancers, but it is not sensitive to some patients with HCC. We obtained datasets from the Gene Expression Omnibus (GEO) database on HCC patients and PD-1 immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Guoming, Zhang, Cheng, Li, Danyun, Luo, Dongqiang, Liao, Hui, Huang, Peizhen, Wang, Ning, Feng, Yibin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953231/ https://www.ncbi.nlm.nih.gov/pubmed/36830729 http://dx.doi.org/10.3390/biom13020360

Ejemplares similares

GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer
por: Chen, Guoming, et al.
Publicado: (2022)

HAMP as a Prognostic Biomarker for Colorectal Cancer Based on Tumor Microenvironment Analysis
por: Wei, Fang-Ze, et al.
Publicado: (2022)

Hamp1 but not Hamp2 regulates ferroportin in fish with two functionally distinct hepcidin types
por: Neves, João V., et al.
Publicado: (2017)

HAMP Domain Conformers That Propagate Opposite Signals in Bacterial Chemoreceptors
por: Airola, Michael V., et al.
Publicado: (2013)

Reply to the letter to the editor by J. Hissbach, S. Zimmermann & W. Hampe
por: Kesternich, Iris, et al.
Publicado: (2017)

Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma
por: Kudo, Yuzan, et al.
Publicado: (2019)

Exploration of novel clusters and prognostic value of immune‑related signatures and identify HAMP as hub gene in colorectal cancer
por: Wu, Hongyuan, et al.
Publicado: (2023)

Sox2 function as a negative regulator to control HAMP expression
por: Song, Bin, et al.
Publicado: (2015)

Characterization of cuproptosis in gastric cancer and relationship with clinical and drug reactions
por: Chen, Guoming, et al.
Publicado: (2023)

Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox
por: Lescano, Manuel A, et al.
Publicado: (2017)

Conformational sampling of CpxA: Connecting HAMP motions to the histidine kinase function
por: Duclert-Savatier, Nathalie, et al.
Publicado: (2018)

Evolutionary gain and loss of a plant pattern-recognition receptor for HAMP recognition
por: Snoeck, Simon, et al.
Publicado: (2022)

HAMP Downregulation Contributes to Aggressive Hepatocellular Carcinoma via Mechanism Mediated by Cyclin4-Dependent Kinase-1/STAT3 Pathway
por: Shen, Ying, et al.
Publicado: (2019)

In silico analysis suggests disruption of interactions between HAMP from hepatocytes and SLC40A1 from macrophages in hepatocellular carcinoma
por: Hu, Liang, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Molecular modeling of the HAMP domain of sensory rhodopsin II transducer from Natronomonas pharaonis
por: Nishikata, Koro, et al.
Publicado: (2010)

Cardiac Hamp mRNA Is Predominantly Expressed in the Right Atrium and Does Not Respond to Iron
por: Bigorra Mir, Maria, et al.
Publicado: (2023)

Differences in DNA methylation of HAMP in blood cells predicts the development of type 2 diabetes
por: Ouni, Meriem, et al.
Publicado: (2023)

Clinical Characteristics and Treatment Overview in Hand-Foot-and-Mouth Disease Using Real-World Evidence Based on Hospital Information System
por: Chen, Guoming, et al.
Publicado: (2022)

DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer
por: Lacalle-Gonzalez, Carlos, et al.
Publicado: (2023)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

HAMP Domain Rotation and Tilting Movements Associated with Signal Transduction in the PhoQ Sensor Kinase
por: Matamouros, Susana, et al.
Publicado: (2015)

The complete chloroplast genome of Rhodobryum laxelimbatum (Hampe ex Ochi) Z. Iwatsuki and T. J. Koponen
por: Li, Shuangling, et al.
Publicado: (2021)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Genetic study of the hepcidin gene (HAMP) promoter and functional analysis of the c.-582A > G variant
por: Parajes, Silvia, et al.
Publicado: (2010)

The HAMP Signal Relay Domain Adopts Multiple Conformational States through Collective Piston and Tilt Motions
por: Zhu, Lizhe, et al.
Publicado: (2013)

Correlation of HAMP gene polymorphisms and expression with the susceptibility and length of hospital stays in Taiwanese children with Kawasaki disease
por: Huang, Ying-Hsien, et al.
Publicado: (2017)

Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway
por: Guangshun, Sun, et al.
Publicado: (2022)

Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights
por: Yu, James, et al.
Publicado: (2023)

CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma
por: Tang, Kaihua, et al.
Publicado: (2023)

H/ACA snoRNP Gene Family as Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma
por: Zhang, Mi, et al.
Publicado: (2021)

Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response
por: Jiang, Hongye, et al.
Publicado: (2021)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Two Distinct States of the HAMP Domain from Sensory Rhodopsin Transducer Observed in Unbiased Molecular Dynamics Simulations
por: Gushchin, Ivan, et al.
Publicado: (2013)

A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma
por: Fan, Sha-Sha, et al.
Publicado: (2017)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2020)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression
por: Zhu, Xiaodan, et al.
Publicado: (2023)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r3pa7unt2gr9qnn6jsuinc0v6i